These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34069639)

  • 1. Design, Synthesis, and Evaluation of Dihydropyranopyrazole Derivatives as Novel PDE2 Inhibitors for the Treatment of Alzheimer's Disease.
    Zhou Y; Li J; Yuan H; Su R; Huang Y; Huang Y; Li Z; Wu Y; Luo H; Zhang C; Huang L
    Molecules; 2021 May; 26(10):. PubMed ID: 34069639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.
    Qiu X; Huang Y; Wu D; Mao F; Zhu J; Yan W; Luo HB; Li J
    Bioorg Med Chem; 2018 Jan; 26(1):119-133. PubMed ID: 29174506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimer's disease.
    Zhang P; Jiang MY; Le ML; Zhang B; Zhou Q; Wu Y; Zhang C; Luo HB
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127254. PubMed ID: 32527553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors.
    Morriello GJ; Dwyer MP; Chen Y; Ginetti AT; Xu S; Lu J; Abeywickrema P; Wang D; Crespo A; Cabalu TD; Wilson JE; Stachel SJ; Paone DV; Sinz C
    Bioorg Med Chem Lett; 2021 Jul; 44():128082. PubMed ID: 33991626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer's disease.
    Jiang MY; Han C; Zhang C; Zhou Q; Zhang B; Le ML; Huang MX; Wu Y; Luo HB
    Bioorg Med Chem Lett; 2021 Jun; 41():128016. PubMed ID: 33838306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
    Li Z; Lu X; Feng LJ; Gu Y; Li X; Wu Y; Luo HB
    Mol Biosyst; 2015 Jan; 11(1):115-25. PubMed ID: 25328054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
    Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB
    ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.
    Huang XF; Cao YJ; Zhen J; Zhang DW; Kong R; Jiang WT; Xu Y; Song GQ; Ke HM; Liu L
    Bioorg Med Chem Lett; 2019 Feb; 29(3):481-486. PubMed ID: 30554955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.
    Zhang C; Feng LJ; Huang Y; Wu D; Li Z; Zhou Q; Wu Y; Luo HB
    J Chem Inf Model; 2017 Feb; 57(2):355-364. PubMed ID: 28055196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of δ-sultone-fused pyrazoles for treating Alzheimer's disease: Design, synthesis, biological evaluation and SAR studies.
    Xu Y; Zhang Z; Jiang X; Chen X; Wang Z; Alsulami H; Qin HL; Tang W
    Eur J Med Chem; 2019 Nov; 181():111598. PubMed ID: 31415981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 2D and 3D-QSAR, molecular modelling and docking studies of pyrazolodiazepinones as novel phosphodiesterase 2 inhibitors.
    Bhansali SG; Kulkarni VM
    SAR QSAR Environ Res; 2014; 25(11):905-37. PubMed ID: 25401514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of novel urolithins derivatives as potential phosphodiesterase II inhibitors.
    Tang L; Jiang J; Song G; Wang Y; Zhuang Z; Tan Y; Xia Y; Huang X; Feng X
    Sci Rep; 2021 Dec; 11(1):23792. PubMed ID: 34893678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease.
    Su T; Zhang T; Xie S; Yan J; Wu Y; Li X; Huang L; Luo HB
    Sci Rep; 2016 Feb; 6():21826. PubMed ID: 26911795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease.
    Umar T; Shalini S; Raza MK; Gusain S; Kumar J; Seth P; Tiwari M; Hoda N
    Eur J Med Chem; 2019 Aug; 175():2-19. PubMed ID: 31055149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
    Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
    Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.
    Zhou LY; Zhu Y; Jiang YR; Zhao XJ; Guo D
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4180-4184. PubMed ID: 28751142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinesterases inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones.
    Shah MS; Khan SU; Ejaz SA; Afridi S; Rizvi SUF; Najam-Ul-Haq M; Iqbal J
    Biochem Biophys Res Commun; 2017 Jan; 482(4):615-624. PubMed ID: 27865835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.
    Pan T; Xie S; Zhou Y; Hu J; Luo H; Li X; Huang L
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2150-2152. PubMed ID: 31281020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.